EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC 4.0

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer

Ronan J Kelly, Katherine Bever, Joseph Chao, Kristen K Ciombor, Cathy Eng, Marwan Fakih, Lipika Goyal, Joleen Hubbard, Renuka Iyer, Holly T Kemberling, Smitha Krishnamurthi, Geoffrey Ku iD und 6 weitere

Journal for ImmunoTherapy of Cancer · 2023-06 · 11 (6) · e006658

DOI: 10.1136/jitc-2022-006658 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 07.06.2023. Verfasst von Ronan J Kelly und 17 weiteren Autor:innen. Beteiligte Einrichtung: Charles A. Sammons Cancer Center, Baylor University Medical Center at Dallas, Dallas, Texas, USA Ronan.Kelly@bswhealth.org. Hauptthemen laut MEDLINE: Quality of Life, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 228 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastrointestinal (GI) cancers, including esophageal, gastroesophageal junction, gastric, duodenal and distal small bowel, biliary tract, pancreatic, colon, rectal, and anal cancer, comprise a heterogeneous group of malignancies that impose a significant global burden. Immunotherapy has transformed the treatment landscape for several GI cancers, offering some patients durable responses and prolonged survival. Specifically, immune checkpoint inhibitors (ICIs) directed against programmed cell death protein 1 (PD-1), either as monotherapies or in combination regimens, have gained tissue site-specific regulatory approvals for the treatment of metastatic disease and in the resectable setting. Indications for ICIs in GI cancer, however, have differing biomarker and histology requirements depending on the anatomic site of origin. Furthermore, ICIs are associated with unique toxicity profiles compared with other systemic treatments that have long been the mainstay for GI cancer, such as chemotherapy. With the goal of improving patient care by providing guidance to the oncology community, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop this clinical practice guideline on immunotherapy for the treatment of GI cancer. Drawing from published data and clinical experience, the expert panel developed evidence- and consensus-based recommendations for healthcare professionals using ICIs to treat GI cancers, with topics including biomarker testing, therapy selection, and patient education and quality of life considerations, among others.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeGastrointestinal NeoplasmsHumansImmunotherapySocieties, Medical

Stichwörter der Autor:innen

gastrointestinal neoplasmsguidelines as topic

Autor:innen und Institutionen

  • Charles A. Sammons Cancer Center, Baylor University Medical Center at Dallas, Dallas, Texas, USA Ronan.Kelly@bswhealth.org.
  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • City of Hope Comprehensive Cancer Center, Duarte, California, USA.
  • Department of Medicine, Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
  • Department of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
  • Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center Duarte, Duarte, California, USA.

ORCID-Profile: Geoffrey Ku, Manish A Shah

Zitieren

APA

Kelly, R. J., Bever, K., Chao, J., Ciombor, K. K., Eng, C., Fakih, M., Goyal, L., Hubbard, J., Iyer, R., Kemberling, H. T., Krishnamurthi, S., Ku, G., Mordecai, M. M., Morris, V. K., Paulson, A. S., Peterson, V., Shah, M. A., & Le, D. T. (2023). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. Journal for ImmunoTherapy of Cancer, 11(6), e006658. https://doi.org/10.1136/jitc-2022-006658

Vancouver

Kelly RJ, Bever K, Chao J, Ciombor KK, Eng C, Fakih M, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. Journal for ImmunoTherapy of Cancer. 2023;11(6):e006658. doi:10.1136/jitc-2022-006658

BibTeX
@article{Kelly2023,
  author = {Kelly, Ronan J and Bever, Katherine and Chao, Joseph and Ciombor, Kristen K and Eng, Cathy and Fakih, Marwan and Goyal, Lipika and Hubbard, Joleen and Iyer, Renuka and Kemberling, Holly T and Krishnamurthi, Smitha and Ku, Geoffrey and Mordecai, Mindy Mintz and Morris, Van K and Paulson, Andrew Scott and Peterson, Valerie and Shah, Manish A and Le, Dung T},
  title = {Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {6},
  pages = {e006658},
  doi = {10.1136/jitc-2022-006658}
}
Kostenlos starten →